Health State Utilities for Non-Small Cell Lung Cancer
Author Information
Author(s): Nafees Beenish, Stafford Megan, Gavriel Sonia, Bhalla Shkun, Watkins Jessamy
Primary Institution: United BioSource Corporation
Hypothesis
The study aims to elicit UK societal based utility values for different stages of NSCLC and associated toxicities.
Conclusion
This study reflects the value that society places on the avoidance of disease progression and severe toxicities in NSCLC.
Supporting Evidence
- Utility scores ranged from 0.673 for responding disease with no toxicity to 0.473 for progressive disease.
- All disease states and toxicities were independent significant predictors of utility.
- Febrile neutropenia was considered the worst toxicity with a utility decrement of -0.090.
Takeaway
This study shows how much people value staying healthy and avoiding side effects from cancer treatment.
Methodology
The study involved cognitive debrief interviews with oncologists and nurses, followed by a societal valuation study where participants rated health states using a standard gamble interview.
Potential Biases
Potential bias in societal preferences as the sample may not fully represent the general population's views on health states.
Limitations
The study may have underestimated the true burden of health-related quality of life impacts due to challenges in recruiting a representative sample of patients experiencing severe toxicities.
Participant Demographics
{"age_mean":40.51,"gender_distribution":{"female":38,"male":62},"ethnic_groups":{"white":74,"black":14,"asian":9,"other":3}}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website